tbuckley/cabot-search huggingface dataset:
Association of Patient and Visit Characteristics With Rate and Timing of Urologic Procedures for Patients Discharged From the Emergency Department With Renal Colic
Authors: Elizabeth M. Schoenfeld, Meng-Shiou Shieh, Penelope S. Pekow, Charles D. Scales, James M. Munger, Peter K. Lindenauer
Journal: JAMA Network Open (2019)

Little is known about the timing of urologic interventions in patients with renal colic discharged from the emergency department. Understanding patients' likelihood of a subsequent urologic intervention could inform decision-making in this population.To examine the rate and timing of urologic procedures performed after an emergency department visit for renal colic and the factors associated with receipt of an intervention.This retrospective cohort study used the Massachusetts All Payers Claims Database to identify patients 18 to 64 years of age who were seen in a Massachusetts emergency department for renal colic from January 1, 2011, to October 31, 2014, Patients were identified via International Classification of Diseases, Ninth Revision codes, and all medical care was linked, enabling identification of subsequent health care use. Data analysis was performed from January 1, 2017, to December 31, 2018.The main outcome was receipt of urologic procedure within 60 days. Secondary outcomes included rates of return emergency department visit and urologic and primary care follow-up.A total of 66 218 unique index visits by 55 314 patients (mean [SD] age, 42.6 [12.4] years; 33 590 [50.7%] female; 25 411 [38.4%] Medicaid insured) were included in the study. A total of 5851 patients (8.8%) had visits resulting in admission at the index encounter, and 1774 (2.7%) had visits resulting in a urologic procedure during that admission. Of the 60 367 patient visits resulting in discharge from the emergency department, 3018 (5.0%) led to a urologic procedure within 7 days, 4407 (7.3%) within 14 days, 5916 (9.8%) within 28 days, and 7667 (12.7%) within 60 days. A total of 3226 visits (5.3%) led to a subsequent emergency department visit within 7 days and 6792 (11.3%) within 60 days. For the entire cohort (admitted and discharged patients), 39 189 (59.2%) had contact with a urologist or primary care practitioner within 60 days. Having Medicaid-only insurance was associated with lower rates of urologic procedures (odds ratio, 0.70; 95% CI, 0.66-0.74) and urologic follow-up (5.6% vs 8.8%; P < .001) and higher rates of primary care follow-up (59.2% vs 47.2%; P < .001) compared with patients with all other insurance types.In this cohort study, most adult patients younger than 65 years who were discharged from the emergency department with a diagnosis of renal colic did not undergo a procedure or see a urologist within 60 days. This finding has implications for both the emergency department and outpatient treatment of these patients.
Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
Authors: K. Park, J. Zhou, D.-W. Kim, A.R. Ahmad, R.A. Soo, R. Bruns, J. Straub, A. Johne, J. Scheele, J.C.-H. Yang, Y.-L. Wu
Journal: Annals of Oncology (2019)
Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice
Authors: Xiaogang Xiang, Dechun Feng, Seonghwan Hwang, Tianyi Ren, Xiaolin Wang, Eszter Trojnar, Csaba Matyas, Ruidong Mo, Dabao Shang, Yong He, Wonhyo Seo, Vijay H. Shah, Pal Pacher, Qing Xie, Bin Gao
Journal: Journal of Hepatology (2019)
Heredity, Environment, and Serum Cholesterol
Authors: LOUIS E. SCHAEFER, DAVID ADLERSBERG, ARTHUR G. STEINBERG
Journal: Circulation (1958)

Serum cholesterol levels of 1,236 healthy persons, including 775 members of 201 families, were analyzed in the investigation of the genetic control of serum cholesterol. It was concluded that there is an important genetic component in the determination of this level in healthy persons, that the gene is probably not sex-linked, and that environmental factors seem to play a lesser role.
Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells
Authors: Zihan Wang, Zihan Geng, Wenwei Shao, Enyang Liu, Jingxuan Zhang, Jingshu Tang, Pingzhang Wang, Xiuyuan Sun, Lin Xiao, Weiyan Xu, Youhui Zhang, Heng Cui, Liang Zhang, Xi Yang, Xiaohong Chang, Xiaoyan Qiu
Journal: Cellular and Molecular Immunology (2019)

To date, IgG in the tumor microenvironment (TME) has been considered a product of B cells and serves as an antitumor antibody. However, in this study, using a monoclonal antibody against cancer-derived IgG (Cancer-IgG), we found that cancer cells could secrete IgG into the TME. Furthermore, Cancer-IgG, which carries an abnormal sialic acid modification in the CH1 domain, directly inhibited effector T-cell proliferation and significantly promoted tumor growth by reducing CD4+ and CD8+ T-cell infiltration into tumor tissues. Mechanistic studies showed that the immunosuppressive effect of sialylated Cancer-IgG is dependent on its sialylation and binding to sialic acid-binding immunoglobulin-type lectins (Siglecs) on effector CD4+ and CD8+ T cells. Importantly, we show that several Siglecs are overexpressed on effector T cells from cancer patients, but not those from healthy donors. These findings suggest that sialylated Cancer-IgG may be a ligand for Siglecs, which may serve as potential checkpoint proteins and mediate tumor immune evasion.
Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Authors: A. Shamshirian, K. Heydari, A.R. Aref, R. Alizadeh-Navaei, D. Shamshirian, Z. Hamzehgardeshi, M. Moosazadeh
Journal: Annals of Oncology (2019)
Helen Salisbury: A chronic problem with language
Authors: Helen Salisbury
Journal: BMJ (2019)

When I was instructed some years ago that the term “chronic disease” had been replaced by “long term condition,” I sighed, inwardly muttering the equivalent of “snowflakes.” But I changed my mind after a little thought and some data gathering among my non-medical friends. To them, “chronic” meant bad or severe. “Acute” also meant severe. I also asked another friend recently, a learned professor in a different field of science, who gave the same answers.

So, if “chronic” means bad, a chronic disease must be a bad one that’s likely to harm or …
Stigma as a fundamental hindrance to the United States opioid overdose crisis response
Authors: Alexander C. Tsai, Mathew V. Kiang, Michael L. Barnett, Leo Beletsky, Katherine M. Keyes, Emma E. McGinty, Laramie R. Smith, Steffanie A. Strathdee, Sarah E. Wakeman, Atheendar S. Venkataramani
Journal: PLoS Medicine (2019)

The current United States opioid overdose crisis is a complex, multifaceted, public health emergency that urgently requires the implementation of evidence-based primary, secondary, and tertiary preventive interventions.We develop a typology of the stigma related to opioid use, showing how multiple dimensions of stigma continue to fundamentally hinder the response to the crisis.• Public stigma is driven by stereotypes about people with opioid use disorders, such as their perceived dangerousness or perceived moral failings, which translate into negative attitudes toward people with opioid use disorders.• Enacted stigma describes the behavioral manifestations of public stigma, including discrimination and social distancing.Public and enacted stigma, in turn, lead to delivery of suboptimal care and undermine access to treatment and harm reduction services.• Public stigma and enacted stigma can become structural stigma when they become encoded in cultural norms, laws, and institutional policies.Collectively, these forms of stigma run at cross purposes to-and reduce public support for-public health-oriented policies to address the opioid overdose crisis.• When people with opioid use disorders internalize or anticipate the public stigma attached to their illness, maladaptive behaviors (e.g., disengagement from care) leading to poorer health outcomes may occur.
NIR‐Emitting Gold Nanoclusters–Modified Gelatin Nanoparticles as a Bioimaging Agent in Tissue
Authors: Nesma El‐Sayed, Vanessa Trouillet, Anne Clasen, Gregor Jung, Klaus Hollemeyer, Marc Schneider
Journal: Advanced Healthcare Materials (2019)

Abstract Gold nanocluster (AuNC) synthesis using a well‐distinguished polymer for nanoparticle‐mediated drug delivery paves the way for developing efficient theranostics based on pharmaceutically accepted materials. Gelatin‐stabilized AuNCs are synthesized and modified by glutathione for tuning the emission spectra. Addition of silver ions enhances the fluorescence, reaching also high quantum yield (26.7%). A simplified model can be proposed describing the nanoclusters' properties–structure relationship based on X‐ray photoelectron spectroscopy data and synthesis sequence. Furthermore, these modifications improve fluorescence stability toward pH changes and enzymatic degradation, offering different AuNCs for various applications. The impact of nanocluster formation on gelatin structure integrity is investigated by Fourier transform infrared spectrometry and matrix‐assisted laser desorption/ionization time of flight mass spectroscopy, being important to further formulate gelatin nanoparticles (GNPs). The 218 nm‐sized NPs show no cytotoxicity up to 600 µg mL −1 and are imaged in skin, as a challenging autofluorescent tissue, by confocal microscopy, when transcutaneously delivered using dissolving microneedles. Linear unmixing allows simultaneous imaging of AuNCs–GNPs and skin with accurate signal separation. This underlines the great potential for bioimaging of this system to better understand nanomaterials' behavior in tissue. Additionally, it is drug delivery system also potentially serving as a theranostic system.
Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa
Authors: Ellie Rashidghamat, Tendai Kadiyirire, Salma Ayis, Gabriela Petrof, Lu Liu, Venu Pullabhatla, Chrysanthi Ainali, Alyson Guy, Sophia Aristodemou, James R. McMillan, Linda Ozoemena, John Mee, Rashida Pramanik, Alka Saxena, Rosamund Nuamah, Emanuele de Rinaldis, Sonia Serrano, Clarisse Maurin, Magdalena Martinez-Queipo, Su M. Lwin, Dusko Ilic, Anna Martinez, Francesco Dazzi, Ineke Slaper-Cortenbach, Kasper Westinga, Sabrina Zeddies, Marcel van den Broek, Alexandros Onoufriadis, Jemima E. Mellerio, John A. McGrath
Journal: Journal of the American Academy of Dermatology (2019)

BackgroundRecessive dystrophic epidermolysis bullosa (RDEB) is a hereditary blistering disorder due to a lack of type VII collagen. At present, treatment is mainly supportive.ObjectivesTo determine whether intravenous allogeneic bone marrow–derived mesenchymal stromal/stem cells (BM-MSCs) are safe in RDEB adults and if the cells improve wound healing and quality of life.MethodsWe conducted a prospective, phase I/II, open-label study recruiting 10 RDEB adults to receive 2 intravenous infusions of BM-MSCs (on day 0 and day 14; each dose 2-4 × 106 cells/kg).ResultsBM-MSCs were well tolerated with no serious adverse events to 12 months. Regarding efficacy, there was a transient reduction in disease activity scores (8/10 subjects) and a significant reduction in itch. One individual showed a transient increase in type VII collagen.LimitationsOpen-label trial with no placebo.ConclusionsMSC infusion is safe in RDEB adults and can have clinical benefits for at least 2 months. Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary blistering disorder due to a lack of type VII collagen. At present, treatment is mainly supportive. To determine whether intravenous allogeneic bone marrow–derived mesenchymal stromal/stem cells (BM-MSCs) are safe in RDEB adults and if the cells improve wound healing and quality of life. We conducted a prospective, phase I/II, open-label study recruiting 10 RDEB adults to receive 2 intravenous infusions of BM-MSCs (on day 0 and day 14; each dose 2-4 × 106 cells/kg). BM-MSCs were well tolerated with no serious adverse events to 12 months. Regarding efficacy, there was a transient reduction in disease activity scores (8/10 subjects) and a significant reduction in itch. One individual showed a transient increase in type VII collagen. Open-label trial with no placebo. MSC infusion is safe in RDEB adults and can have clinical benefits for at least 2 months.
Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome
Authors: Gerben Duns, Elena Viganò, Daisuke Ennishi, Clementine Sarkozy, Stacy Hung, Elizabeth Chavez, Katsuyoshi Takata, Anja Mottok, Randy D. Gascoyne, Ryan D. Morin, Kerry J Savage, David W. Scott, Christian Steidl
Journal: Blood (2019)
Abstract 25: Prognostic Role of NT-ProBNP in Out-Of-Hospital Cardiac Arrest
Authors: David E Hamilton, Bradley J Petek, Lindsay G Panah, Sean R Mendez, Philip E Dormish, Michael G Silverman
Journal: Circulation (2019)

Introduction: The role of cardiac biomarkers in patients after out-of-hospital cardiac arrest (OHCA) has been subject to recent research due to myocardial stress and injury associated with cardiac arrest. However, it remains unclear to what extent NT-proBNP can be used as a prognostic tool after OHCA. Hypothesis: Baseline NT-proBNP is an independent predictor of mortality in patients after OHCA. Methods: Multicenter retrospective observational cohort study including non-traumatic OHCA patients presenting from 2/1/2017 to 4/1/2019. Relationship between NT-proBNP quartiles and mortality was assessed through unadjusted and adjusted (age, gender, presenting rhythm) analyses with logistic regression. Results: Baseline NT-proBNP values were obtained for 283 patients on presentation after OHCA with median 965 pg/mL (IQR 157-3550). Levels did not differ by arrest etiology (cardiac vs noncardiac) or presenting rhythm. NT-proBNP levels correlated with age (r = 0.44, p&lt;0.0001), but not with lactate, CPR duration, or intra-arrest epinephrine. Overall in-hospital mortality was 68% (196/283). Mortality increased in a stepwise fashion among patients in increasing quartiles of NT-proBNP level (Figure). Mortality rate in Q1: 59% ( 42/71), Q2: 61% (43/70), Q3: 75% (54/72), Q4: 77% (54/70). Odds Ratios (OR) vs Q1 as reference: Q2 OR 1.10 [95% CI 0.56-2.17] p= 0.48; Q3 OR 2.08 [95% CI 1.01-4.17] p= 0.045; Q4 OR 2.33 [95% CI 1.11-4.76] p=0. 023. After adjusting for age, gender, and shockable rhythm there remained a stepwise relationship between higher mortality with increasing NT-proBNP quartile (Q2 OR 1.30 [95% CI 0.61-2.78] p= 0.78; Q3 OR 2.33 [95% CI 1.05-5.26] p= 0.038; Q4 OR 2.50 [95% CI 1.05-5.88] p= 0.039). Conclusion: In this multicenter cohort of patients with shockable and nonshockable OHCA, increased levels of NT-proBNP were predictive of an increased risk of in-hospital mortality even after adjustment for age, gender, and presenting rhythm.
Conceptualising trauma in women with long term health needs from violence
Authors: Ayesha Ahmad
Journal: BMJ (2019)

The educational focus of Ades and colleagues’ article is crucial for ensuring that women with long term health needs from violence are not marginalised in the clinical setting.1 But it is also important to include a nuanced conceptual and critical approach to the framing of such women’s trauma.

Reducing a woman to her suffering negates the ways that she …
Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury
Authors: William E Plautz, Mitchell Dyer, Margaret V. Ragni, Shannon Haldeman, Wyeth E Alexander, Jason Sperry, Francis Guyette, Brian Zuckerbraun, Marian A. Rollins-Raval, Jay S Raval, Matthew D Neal
Journal: Blood (2019)
Single-Cell Profiles of Retinal Ganglion Cells Differing in Resilience to Injury Reveal Neuroprotective Genes
Authors: Nicholas M. Tran, Karthik Shekhar, Irene E. Whitney, Anne Jacobi, Inbal Benhar, Guosong Hong, Wenjun Yan, Xian Adiconis, McKinzie E. Arnold, Jung Min Lee, Joshua Z. Levin, Dingchang Lin, Chen Wang, Charles M. Lieber, Aviv Regev, Zhigang He, Joshua R. Sanes
Journal: Neuron (2019)
Could Tobacco Control Policies Be a Smokescreen?—Reply
Authors: G. Emmanuel Guindon, Guillermo R. Paraje, Frank J. Chaloupka
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Depression in lung cancer patients: A nationwide analysis.
Authors: Arya Mariam Roy, Manojna Konda, Aravind Mohanakumar Warrier, Konstantinos Arnaoutakis
Journal: Journal of Clinical Oncology (2019)

83 Background: Depression is a major ongoing problem with cancer patients and survivors. Depression can lead to functional impairment, decreased utilization of treatment, decreased quality of life and increased suicide risk. It also leads to an extended hospital stay and increased cost of treatment. Previous studies have shown that lung cancer has a high incidence for depression. Methods: We conducted a cross-sectional study using the National Inpatient Sample (NIS) database for the year 2016. Patients who were admitted with a principal diagnosis of Malignant Neoplasm of Bronchus and Lung (MNBL) and Major Depressive Disorder (MDD) were identified using ICD-10 codes. The prevalence of MDD and the risk factors contributing to MDD were studied. Statistical analysis was performed using STATA tool and tested with Pierson Chi-Square test. Results: A total of 79096 hospitalizations with a principal diagnosis of MNBL were identified. The prevalence of depression among lung cancer patients was found to be 12.49% (n = 9881). The mean age of lung cancer patients with depression was 62.27 ± 0.10. Females with lung cancer have more risk for MDD (15%, p &lt; 0.001). Caucasian patients with lung cancer have a higher risk of MDD (13.6%, p &lt; 0.001). It was also found that lung cancer patients who are ≤ 55 years have a higher risk of MDD (p &lt; 0.001). The average length of stay for lung cancer patients with MDD was slightly higher than lung cancer patients without MDD (6.39 days and 5.99 days respectively). The average cost of stay also had a similar pattern. Severe morbidity was seen in a greater proportion of the MDD group. Conclusions: Younger patients who are ≤ 55 years of age, Caucasians or females with lung cancer have a higher risk of MDD. Particular attention should be given to them while being in the hospital which can decrease the morbidity, and will also help to improve their quality of life.
Ranitidine: all products are out of stock as investigations continue
Authors: Elisabeth Mahase
Journal: BMJ (2019)

All ranitidine products (injectable and oral) are “expected to be out of stock with no date for resupply until further notice,” the Department of Health and Social Care has told doctors.1

In an updated statement, the department added injectable products to the list of ranitidine products that should no longer be prescribed. …
Association of troponin level and age with mortality in 250 000 patients: cohort study across five UK acute care centres
Authors: Amit Kaura, Vasileios Panoulas, Benjamin Glampson, Jim Davies, Abdulrahim Mulla, Kerrie Woods, Joe Omigie, Anoop D Shah, Keith M Channon, Jonathan N Weber, Mark R Thursz, Paul Elliott, Harry Hemingway, Bryan Williams, Folkert W Asselbergs, Michael O’Sullivan, Rajesh Kharbanda, Graham M Lord, Narbeh Melikian, Riyaz S Patel, Divaka Perera, Ajay M Shah, Darrel P Francis, Jamil Mayet
Journal: BMJ (2019)

Abstract Objective To determine the relation between age and troponin level and its prognostic implication. Design Retrospective cohort study. Setting Five cardiovascular centres in the UK National Institute for Health Research Health Informatics Collaborative (UK-NIHR HIC). Participants 257 948 consecutive patients undergoing troponin testing for any clinical reason between 2010 and 2017. Main outcome measure All cause mortality. Results 257 948 patients had troponin measured during the study period. Analyses on troponin were performed using the peak troponin level, which was the highest troponin level measured during the patient’s hospital stay. Troponin levels were standardised as a multiple of each laboratory’s 99th centile of the upper limit of normal (ULN). During a median follow-up of 1198 days (interquartile range 514-1866 days), 55 850 (21.7%) deaths occurred. A positive troponin result (that is, higher than the upper limit of normal) signified a 3.2 higher mortality hazard (95% confidence interval 3.1 to 3.2) over three years. Mortality varied noticeably with age, with a hazard ratio of 10.6 (8.5 to 13.3) in 18-29 year olds and 1.5 (1.4 to 1.6) in those older than 90. A positive troponin result was associated with an approximately 15 percentage points higher absolute three year mortality across all age groups. The excess mortality with a positive troponin result was heavily concentrated in the first few weeks. Results were analysed using multivariable adjusted restricted cubic spline Cox regression. A direct relation was seen between troponin level and mortality in patients without acute coronary syndrome (ACS, n=120 049), whereas an inverted U shaped relation was found in patients with ACS (n=14 468), with a paradoxical decline in mortality at peak troponin levels &gt;70×ULN. In the group with ACS, the inverted U shaped relation persisted after multivariable adjustment in those who were managed invasively; however, a direct positive relation was found between troponin level and mortality in patients managed non-invasively. Conclusions A positive troponin result was associated with a clinically important increased mortality, regardless of age, even if the level was only slightly above normal. The excess mortality with a raised troponin was heavily concentrated in the first few weeks. Study registration ClinicalTrials.gov NCT03507309 .
Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Authors: Meng Wang, Iulian Pruteanu, Adam D. Cohen, Alfred L Garfall, Michael C. Milone, Lifeng Tian, Vanessa E. Gonzalez, Saar Gill, Noelle V. Frey, David M. Barrett, Marco Ruella, Simon F Lacey, Jakub Svoboda, Elise A. Chong, Joseph A Fraietta, Megan Davis, Sunita D Nasta, Bruce L Levine, Don L. Siegel, Shannon L. Maude, Stephen J. Schuster, Edward A. Stadtmauer, Stephan Grupp, David L. Porter, Carl H June, J. Joseph Melenhorst
Journal: Blood (2019)
Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy
Authors: Vindi Jurinovic, Verena Passerini, Mikkel Z Oestergaard, Andrea Knapp, Kirsten Mundt, Shamzah Araf, Julia Richter, Jude Fitzgibbon, Wolfram Klapper, Robert E. Marcus, Andrew Davies, Michael Herold, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert
Journal: Blood (2019)